Catalent has acquired the Vaccine Manufacturing Innovation Centre in Harwell, Oxford to expand its biologics capabilities across the UK and Europe.
Catalent announced on April 6, 2022 that it has acquired Vaccine Manufacturing and Innovation Centre UK Limited’s biologics development and manufacturing facility currently under construction near Oxford, United Kingdom. Catalent plans to invest up to US$160 million (£120 million) into the completion of the construction of the facility.
The focus of the facility will be to develop and manufacture biologic therapies and vaccines, including messenger RNA, proteins, and other advances modalities. The facility is expected to employ more than 400 people once completed as well as support public and private organizations looking to develop and manufacture biotherapeutics.
Catalent’s workforce in the UK already exceeds 1300 people at its four facilities, located in Nottingham, Swindon, Haverhill, and Dartford. The company also has sites in Italy, Belgium, France, Switzerland, and the United States.
“This acquisition allows Catalent to collaborate with the rich academic and biomedical science community centered around Oxford, with its world-class talent, and will result in a facility that provides opportunities to transform innovation into real treatments for patients across the United Kingdom, Europe, and beyond,” commented Mike Riley, president of Catalent Biotherapeutics, in a press release. “Our priority is to complete construction as soon as possible to be able to commence customer programs in 2022. We will then integrate its capabilities within our existing network of biologics facilities across Europe to offer a flexible range of manufacturing, technology, and development solutions for the pipeline of thousands of development programs currently underway.”
Source: Catalent
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.